Enanta Pharmaceuticals reported financial results for the fiscal fourth quarter and year-ended September 30, 2025.
The company announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor.
Positive topline data was reported for RSVHR, a Phase 2b study of Zelicapavir in high-risk adults infected with RSV.
EPS-3903 Development
EPS-3903 is an oral STAT6 inhibitor showing rapid, continuous, and complete pSTAT6 suppression, with efficacy comparable to Dupilumab in asthma and atopic dermatitis disease models.
EDP-978 Nomination
EDP-978 is an oral KIT inhibitor clinical candidate planned for treatment of mast-cell driven diseases, with an IND filing expected in Q1 2026.
Revenue Results
Total revenue was $15.1 million for the fiscal fourth quarter, driven by royalty revenue from AbbVie's MAVYRET/MAVIRET, and $65.3 million for the year-ended September 30, 2025.
- Enanta Pharmaceuticals showcased a strong financial position with $188.9 million in cash, cash equivalents, and marketable securities at the end of fiscal 2025.
- The company reported a positive response to the RSVHR study, indicating zelicapavir's potential in reducing RSV symptoms in high-risk adults.
- The development of EPS-3903 and EDP-978 highlights Enanta's commitment to advancing treatments for immunological diseases.
Enanta Pharmaceuticals' progress in its virology and immunology programs, along with the positive financial results, sets a promising trajectory for the company's future growth and innovation.